Table 1.
List of ongoing clinical trials combining a poly-ADP ribose polymerase (PARP) inhibitor with an ATR inhibitor. Information obtained from https://clinicaltrials.gov, accessed March 9 2020.
| Clinical Trial Number | PARP Inhibitor | ATR Inhibitor | Other Therapy/Status | Cancer Type |
|---|---|---|---|---|
| NCT02723864 | Veliparib/ABT-888 | VX-970 | Cisplatin | Refractory Solid Tumours |
| NCT034R2342 | Olaparib | AZD6738 | Platinum-sensitive or platinum-resistant | Recurrent ovarian cancer (CAPRI trial) |
| NCT03682289 | Olaparib | AZD6738 | None stated | Renal cell carcinoma, urothelial carcinoma, pancreatic cancers and other solid tumours |
| NCT03787680 | Olaparib | AZD6738 | DNA repair proficient/DNA repair deficient | Metastatic Castration-Resistant Prostate Cancer (TRAP trial) |
| NCT04065269 | Olaparib | AZD6738 | ARID1A loss versus no loss | Relapsed gynaecological cancers |
| NCT04267939 | Niraparib | BAY1895344 | Recurrent Advanced Solid Tumours and Ovarian Cancer |